• Artificial Intelligence (AI)
• Regulatory Affairs
• February 23, 2026

New multilingual AI agents are designed to help MedTech teams identify narrative and traceability breaks across intended use, risk controls, testing, and labeling before filing

PALO ALTO, Calif., Feb. 11, 2026i-GENTIC AI today announced a new suite of context-aware, multilingual MedTech agents designed to help medical device manufacturers improve the quality and consistency of FDA 510(k) submissions. Preparing a 510(k) often takes months, yet many submissions require additional information requests or are rejected due to inconsistencies across documents, evidence, and claims, creating delays and added costs for manufacturers.

The company's platform, powered by its GENIE™ reasoning engine, is designed to function as a continuous pre-submission review layer that surfaces mismatches across the submission narrative, including drift between intended use, design assumptions, performance testing, risk controls, and labeling. According to i-GENTIC AI internal engagement data, customers have improved first-time submission success rates by up to 97 percent and reduced approval timelines by an average of six weeks.

"FDA reviewers look for a consistent narrative," said Zahra Timsah, founder and CEO of i-GENTIC AI. "They need to see that evidence, logic, and traceability for your device remain solid across the entire submission."

The core submission problem: inconsistency, not missing documents

A 510(k) submission typically includes extensive documentation across intended use, risk management, verification and validation, performance testing, and labeling. Even when every individual document is complete, inconsistencies between documents can create a fragmented story. When the evidence and claims stop aligning, reviewers may issue requests for additional information or halt review until issues are resolved, extending timelines and increasing costs.

"Our agents are built to surface where that narrative fractures," Timsah said. "They identify when an intended use statement drifts from the design assumptions it was based on, when performance testing no longer supports the claim being made, or when a documented risk control no longer mitigates the real-world behavior of the device. That is the level of scrutiny teams face during FDA reviews, and that is the level of scrutiny MedTech teams need before they submit."

Timsah has previously held executive roles at IQVIA, MassMutual, and GSK.

Industry leadership perspective on scale and complexity

Former Medtronic CTO Dr. Ken Washington, now Chairman of the Board at i-GENTIC AI, has overseen regulatory and technology strategy across large-scale medical device portfolios.

"Traditional systems act like a basic checklist, telling you that a document exists," Washington said. "But they cannot tell you whether the data still makes sense after months of design changes and internal reviews."

"As device portfolios scale, complexity grows faster than teams can manually track across systems. Context-aware agents can help surface weak links early, when teams still have time to fix them thoughtfully rather than discovering them later through regulatory back-and-forth."

Scott Van Valkenburgh, board member at i-GENTIC AI and SVP at low-code automation platform Appian, added that AI-driven compliance changes the economics of the 510(k) process.

"Speed to clearance is a major competitive advantage," Van Valkenburgh said. "General-purpose AI tools are rarely designed for the rigor of FDA scrutiny. Regulations exist to protect patients, and context-aware agents can help MedTech teams reach clearance faster while maintaining the discipline that review demands."

Finding the break before review: a regulatory case study

In a recent engagement, a MedTech firm's 510(k) documentation passed internal checks, yet i-GENTIC AI's agents flagged a critical issue: a late-stage change to the intended use no longer aligned with the risk analysis and test results.

No individual document was incorrect. The collective set of documents, however, told an inconsistent story. The agents traced the logic break across the Design History File and flagged the misalignment. By correcting the issue prior to filing, the team avoided a likely FDA request for additional information or rejection driven by cross-document inconsistency.

Beyond 510(k)

While the 510(k) pathway is a common bottleneck, i-GENTIC AI's platform is designed for broader use across regulated industries where traceability, internal consistency, and evidence-backed decisioning matter. The same approach can be applied to complex regulations, SOPs, and governance frameworks where teams must maintain alignment across documents, systems, and workflows.

i-GENTIC AI is a member of AdvaMed, the MedTech association that advocates for ethical business practices.

About i-GENTIC AI

i-GENTIC AI builds agentic AI systems for regulated industries, starting with MedTech. Its GENIE™ platform delivers a unified reasoning engine that orchestrates specialized AI agents across workflows, documents, and systems, providing continuous, context-aware regulatory intelligence to support submission readiness and compliance operations.

For more information, visit igenticai.com.

Media Contact

Zahra Timsah
Founder and CEO, i-GENTIC AI
[email protected]

###

Share this article:

• Share this page on Twitter
• Share this page on Facebook
• Share this page on LinkedIn
• Email a link to this page

Related Reading

Blog / Regulatory Affairs

Why Practical FDA Submissions Training Makes the Difference

February 17, 2026

Explore AdvaMed's Medical Device Submissions Workshop Series from practical submission strategies to live expert insights you can apply immediately.

News / Coverage & Payment / Diagnostics / Regulatory Affairs

AdvaMed Announces Melissa Torres as New Executive Vice President of Technology and Regulatory Affairs

February 10, 2026

WASHINGTON-AdvaMed, the Medtech Association, today announced Melissa Torres is the new Executive Vice President of Technology and Regulatory Affairs. Torres succeeds Janet Trunzo, who retired after 30 distinguished, productive years with AdvaMed.

News / Diagnostics / Digital Health / Medical Imaging / Regulatory Affairs

AdvaMed Receives RAPS Accreditation for Medical Device Submissions Workshop Series (February 2026 in Washington, D.C.)

February 4, 2026

WASHINGTON, D.C.-AdvaMed, the world's largest trade association representing medical technology innovators, announced that its Medical Device Submissions Workshop Series (February 23-27 in Washington, D.C.) has been officially approved for RAC recertification credits by the Regulatory Affairs Professionals Society (RAPS).

Blog / Artificial Intelligence (AI) / Diagnostics / Digital Health / Health Access

The Insight Series: AI & Digital Health

January 30, 2026

AdvaMed Digital Health Tech division member companies include world leaders in developing AI-enabled solutions to improve health and care, from diagnosis to treatment, clinical decision support, and wearables to wellness. "The Insight Series: AI & Digital Health" will feature company experts, answering pressing questions to inform policymakers and the public about how AI and digital health are transforming care and delivery. Our inaugural entry is a conversation between Melissa Cha of Amazon and Taha Kass-Hout of GE HealthCare.

Blog / Diagnostics / Digital Health / Regulatory Affairs / Standards

Honoring Janet E. Trunzo: A Legacy That Shaped Modern Medtech Regulation

January 29, 2026

After 30 years at AdvaMed, Janet E. Trunzo, Senior Advisor to the President and Senior Executive Vice President of Technology and Regulatory Affairs, will retire on January 31, 2026. Her tenure has fundamentally shaped how medical devices are regulated in the United States and globally, establishing frameworks and standards that continue to govern the field today.

Blog / Regulatory Affairs

Strengthen Your IDE Strategy at AdvaMed's IDE Submissions Workshop

January 27, 2026

Gain in-depth IDE submission training, meaningful face time with FDA and regulatory leaders, and RAPS accreditation credits at AdvaMed's IDE Submissions Workshop.

Blog / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access / Medical Imaging

Why the Health Tech Investment Act Matters: Peter Weems Breaks Down What This Means for Patients

January 26, 2026

In a new video developed in partnership with Patients Rising, AdvaMed's Peter Weems, Vice President of Imaging Government Affairs and Policy Strategy, explains why the Health Tech Investment Act is critical to expanding patient access to FDA-authorized AI-enabled medical devices.

News / Coverage & Payment / Diagnostics / Regulatory Affairs

AdvaMed Names Brian J. Blaser, QuidelOrtho President and CEO, Chair of AdvaMedDx Board of Directors

January 21, 2026

WASHINGTON, D.C.-AdvaMed, the Medtech Association, today announced that Brian Blaser, president and CEO of QuidelOrtho, will serve as the next chair of the AdvaMedDx Division Board of Directors, succeeding Thierry Bernard, CEO of QIAGEN. AdvaMedDx represents more than 70 manufacturers of the innovative in vitro diagnostic (IVD) tests critical to patient care.